Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.
Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M. Giacchetti S, et al. Among authors: de the h, de roquancourt a. Br J Cancer. 2014 Mar 18;110(6):1413-9. doi: 10.1038/bjc.2014.81. Epub 2014 Feb 25. Br J Cancer. 2014. PMID: 24569467 Free PMC article.
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H. Bertheau P, et al. Among authors: de the h, de reynies a, de roquancourt a. PLoS Med. 2007 Mar;4(3):e90. doi: 10.1371/journal.pmed.0040090. PLoS Med. 2007. PMID: 17388661 Free PMC article.
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M. Groheux D, et al. Among authors: de cremoux p, de roquancourt a. Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15. Cancer. 2013. PMID: 23504954 Free article.
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M. Groheux D, et al. Among authors: de cremoux p, de roquancourt a. Eur J Cancer. 2014 Jul;50(11):1864-71. doi: 10.1016/j.ejca.2014.04.020. Epub 2014 May 16. Eur J Cancer. 2014. PMID: 24841218
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D, Biard L, Giacchetti S, Teixeira L, Hindié E, Cuvier C, Vercellino L, Merlet P, de Roquancourt A, de Cremoux P, Resche-Rigon M, Espié M. Groheux D, et al. Among authors: de roquancourt a. J Nucl Med. 2016 Apr;57(4):536-43. doi: 10.2967/jnumed.115.163907. Epub 2015 Dec 23. J Nucl Med. 2016. PMID: 26697967 Free article.
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Cottu PH, Extra JM, Espie M, Marolleau JP, de Roquancourt A, Makke J, Miclea JM, Laurence V, Mayeur D, Lerebours F, Cuvier C, Marty M. Cottu PH, et al. Among authors: de roquancourt a. Br J Cancer. 2001 Nov 2;85(9):1240-6. doi: 10.1054/bjoc.2001.2069. Br J Cancer. 2001. PMID: 11720455 Free PMC article. Clinical Trial.
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.
Varna M, Soliman H, Feugeas JP, Turpin E, Chapelin D, Legrès L, Plassa LF, de Roquancourt A, Espié M, Misset JL, Janin A, de Thé H, Bertheau P. Varna M, et al. Among authors: de the h, de roquancourt a. Br J Cancer. 2007 Oct 22;97(8):1157-64. doi: 10.1038/sj.bjc.6603937. Epub 2007 Sep 18. Br J Cancer. 2007. PMID: 17876337 Free PMC article.
Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.
Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, de Roquancourt A, Plassa LF, Giacchetti S, Espié M, de Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, de Thé H, Bertheau P. Lehmann-Che J, et al. Among authors: de bazelaire c, de the h, de roquancourt a. Br J Cancer. 2011 May 24;104(11):1739-46. doi: 10.1038/bjc.2011.135. Epub 2011 May 3. Br J Cancer. 2011. PMID: 21540864 Free PMC article.
86 results